CLOSE
Filing date: 9 Dec, 2020
EP20383072.4
ICREA selecciona els investigadors únicament segons els seus mèrits científics. No obstant això, l'excel·lència científica porta sovint a la invenció de noves tecnologies i solucions. Quan passa això, ICREA fa costat a l'aprofitament d'aquestes oportunitats.
Els catedràtics de recerca de la ICREA treballen a diverses universitats i centres de recerca. Per això la titularitat de qualsevol propietat industrial es comparteix sempre entre la ICREA i la institució d'acollida. Perquè les negociacions siguin el més àgils i concloents possible, les institucions d'acollida tenen plena llibertat per emprendre activitats de transferència de tecnologia en nom d'ICREA, si en sorgeix l'oportunitat. ICREA recolza les accions encaminades a aquest aprofitament i presta assessorament al llarg de tot el procés.
Consulteu les nostres tecnologies actuals i contacteu amb ICREA per saber-ne més.
-
CLOSE
Chimeric antigen receptors specific for P95HER2 and uses thereof
La presente invención se refiere a un receptor de antígeno quimérico (CAR) capaz de 5 dirigirse a células que expresan p95HER2. La invención también se refiere a un fragmento variable de cadena sencilla (ScFv), a un dominio de unión a antígeno y a un anticuerpo o fragmento de anticuerpo del mismo capaz de unirse al antígeno p95HER2. Además, la presente invención se refiere a un conjugado anticuerpo-fármaco (ADC) que comprende un agente terapéutico y un anticuerpo o dominio de unión a antígeno 10 específico para p95HER2. La invención también se refiere a un método de diagnóstico de cáncer y a una composición farmacéutica para su uso en un método de prevención o tratamiento del cáncer que comprenden el CAR y/o el dominio de unión a antígeno o el anticuerpo de la invención.
VHIO
Filing date: 12 Jun, 2020
Licenced date: 11 Dec, 2020
EP20382457.8
-
CLOSE
CD22 Targeting-moiety for the treatment of B-cell acute lymphoblastic Leukemia (B-ALL).
The present invention provides therapeutics for the treatment of CD22-positive cancers such as B-cell acute lymphoblastic eukemia (B-ALL). In particular, the present invention provides an anti-CD22 monoclonal antibody whose F(AB')2, particularly the scFv fragment, can target the CD22 antigen, for use in the treatment of CD22-positive cancers.
IJC
Filing date: 11 Mar, 2020
Licenced date: 16 Jul, 2020
EP20382175.6
-
CLOSE
Pulmobiotics
TM - Extended to US within priority period (before 14/08) / Licensed to Pulmobiotics S.L.
Center for Genomic Regulation
Filing date: 14 Feb, 2020
Licenced date: 14 Aug, 2020
018196643
-
CLOSE
Method to photo-capture CO2 with perovskite oxide compounds
The present application refers to a method for CO2 capture wherein light, particularly ultraviolet illumination, greatly improves the amount of CO2 captured on engineered perovskite oxide compounds. By a photorefractive phenomenon under near ultraviolet illumination, ionized defects are created at the surface of B-site defective oxide perovskites which act as additional CO2 trapping centres. The present method can be implemented at a temperature between -10ºC and 80ºC, and is cyclable, i.e. the perovskite oxide compounds can be regenerated by heat and used for subsequent CO2 capture.
ICN2
Filing date: 30 Dec, 2019
PCT/EP2020/088044
-
CLOSE
Gene editing based cancer treatment
Filing date: 14 Oct, 2019
PCT/EP2019/078408
-
CLOSE
Title confidential - not published yet
ICFO
Filing date: 30 Sep, 2019
US62/908,079
-
CLOSE
A microstructured film comprising inorganic-organic hybrid polymers, a method for manufacturing thereof and a method for cooling the surface of an element by applying said microstructured film.
The present invention relates to a microstructured film comprising an inorganic-organic hybrid polymer which is capable to cool down and to keep clean the surface on which it is applied on. The present invention further relates to a method for manufacturing said microstructured film and to a method for cooling the surface of an element by applying said microstructured film.
ICN2
Filing date: 30 Jul, 2019
PCT/EP19382655/071560
-
CLOSE
Electrochemical cell device for use in a SOFC and/or a SOEC and methods for operating a SOFC or a SOEC by using thereof.
The present invention relates to the field of electrochemistry. In particular, the present invention relates to an electrochemical cell device for use in a solid oxide fuel cell (SOFC) and/or a solid oxide electrolyser cell (SOEC) mode, and to a method for operating a solid oxide fuel cell and/or a solid oxide electrolyser cell by using said electrochemical cell device.
IREC
Filing date: 18 Jun, 2019
EP19382509
-
CLOSE
FLUIDIC APPARATUS FOR OPTICAL INTERROGATION OF INDIVIDUAL MICROORGANISMS
Filing date: 18 Apr, 2019
PCT/ES2019/070270